Kidney, the Cinderella Story of Transthyretin Amyloidosis.
作者信息
Leung Nelson
机构信息
Division of Nephrology and Hypertension, Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
出版信息
Kidney Int Rep. 2025 May 1;10(6):1622-1624. doi: 10.1016/j.ekir.2025.04.050. eCollection 2025 Jun.
Abstract
摘要
相似文献
1
Kidney, the Cinderella Story of Transthyretin Amyloidosis.
Kidney Int Rep. 2025 May 1;10(6):1622-1624. doi: 10.1016/j.ekir.2025.04.050. eCollection 2025 Jun.
2
Kidney Outcomes in Patients With Hereditary Transthyretin Amyloid Nephropathy Treated With Transthyretin Stabilizers And Gene-Silencer Therapies.
Kidney Int Rep. 2025 Mar 24;10(6):1939-1949. doi: 10.1016/j.ekir.2025.03.029. eCollection 2025 Jun.
3
The impact of limited healthcare access among patients with light chain and transthyretin amyloidosis: real-world survey during COVID-19 lockdown period in France.
Orphanet J Rare Dis. 2025 Jul 8;20(1):347. doi: 10.1186/s13023-025-03859-1.
4
QTc interval prolongation as a marker of disease stage in transthyretin cardiac amyloidosis.
Clin Res Cardiol. 2025 Jul 3. doi: 10.1007/s00392-025-02680-x.
5
Prognostic Value of Malnutrition, Frailty, and Physical Performance in Transthyretin Cardiac Amyloidosis: Insights From a Prospective Multicenter Cohort Study.
Circ Heart Fail. 2025 Jul 2:e012777. doi: 10.1161/CIRCHEARTFAILURE.125.012777.
6
Therapeutic effect of TTR siRNA on hereditary transthyretin amyloidosis (ATTRv) nephropathy.
Amyloid. 2025 Jun;32(2):171-178. doi: 10.1080/13506129.2025.2470369. Epub 2025 Feb 23.
7
Pathological spectrum of hereditary transthyretin renal amyloidosis and clinicopathologic correlation: a French observational study.
Nephrol Dial Transplant. 2023 Aug 31;38(9):2019-2030. doi: 10.1093/ndt/gfad006.
8
Historic characteristics and mortality of patients in the Swiss Amyloidosis Registry.
Swiss Med Wkly. 2024 Feb 15;154:3485. doi: 10.57187/s.3485.
9
The use of diflunisal for transthyretin cardiac amyloidosis: a review.
Heart Fail Rev. 2022 Mar;27(2):517-524. doi: 10.1007/s10741-021-10143-4. Epub 2021 Jul 16.
10
Unraveling gut microbiome alterations and metabolic signatures in hereditary transthyretin amyloidosis.
Microbiol Spectr. 2025 Jul;13(7):e0230224. doi: 10.1128/spectrum.02302-24. Epub 2025 May 23.
本文引用的文献
1
Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee.
Amyloid. 2024 Dec;31(4):249-256. doi: 10.1080/13506129.2024.2405948. Epub 2024 Sep 30.
2
2024 Update on Classification, Etiology, and Typing of Renal Amyloidosis: A Review.
Am J Kidney Dis. 2024 Sep;84(3):361-373. doi: 10.1053/j.ajkd.2024.01.530. Epub 2024 Mar 19.
3
Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
Eur J Heart Fail. 2023 Apr;25(4):515-524. doi: 10.1002/ejhf.2776. Epub 2023 Jan 30.
4
Sex differences among patients with transthyretin amyloid cardiomyopathy - from diagnosis to prognosis.
Eur J Heart Fail. 2022 Dec;24(12):2355-2363. doi: 10.1002/ejhf.2646. Epub 2022 Aug 16.
5
Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.
J Neurol. 2021 Jun;268(6):2109-2122. doi: 10.1007/s00415-019-09688-0. Epub 2020 Jan 6.
6
Senile systemic amyloidosis: clinical features at presentation and outcome.
J Am Heart Assoc. 2013 Apr 22;2(2):e000098. doi: 10.1161/JAHA.113.000098.
7
Transthyretin amyloidosis and the kidney.
Clin J Am Soc Nephrol. 2012 Aug;7(8):1337-46. doi: 10.2215/CJN.08720811. Epub 2012 Apr 26.
8
End-stage renal disease and dialysis in hereditary amyloidosis TTR V30M: presentation, survival and prognostic factors.
Amyloid. 2004 Mar;11(1):27-37. doi: 10.1080/13506120410001673884.
Zotero 插件